Michael Palayew

Papers

Total Citations

H-Index

About

Michael Palayew is a clinical researcher whose work focuses on the treatment of motor complications in Parkinson’s disease, particularly levodopa-induced dyskinesia (LID). His major contribution lies in systematically reviewing and synthesizing the landscape of ongoing and recent clinical trials for LID, providing a critical overview of both pharmacological and non-pharmacological interventions. His most cited paper, "Recent and on-going trials for the treatment of levodopa-induced dyskinesia: a review of the clinical trial databases" (2025, 4 citations), highlights the mixed outcomes of emerging therapies—such as the 5-HT1A/1B agonist zolmitriptan, which failed to meet Phase II endpoints—while pointing to promising non-pharmacological approaches like robot-assisted repetitive transcranial magnetic stimulation (rTMS) of the pre-supplementary motor area. This work serves as a valuable resource for researchers and clinicians navigating the challenging therapeutic landscape of LID. Palayew’s research is notable for its translational relevance, bridging clinical trial data with practical treatment insights. His contributions are especially impactful for students and researchers interested in movement disorders, clinical trial design, and novel neuromodulation strategies.